Efficacy of Neoadjuvant Therapy for Resectable Pancreatic Cancer Might be Limited to Biologically Borderline Resectable Cases
Authors:
- 3 March 2025
- journal article
- research article
- Published by Wolters Kluwer Health in Pancreas
- Vol. 54 (7) , e630-e636
Abstract
Background: Neoadjuvant therapy (NAT) followed by surgery is becoming a standard treatment even for resectable pancreatic cancer (RPC). However, it is unclear whether NAT is necessary for all RPC cases. Methods: A total of 296 patients diagnosed with RPC and under 80 years old were retrospectively analyzed, focusing on tumor markers (TMs). The cutoff value of TM was decided based on the classification by the International Association of Pancreatology. Results: Among 80 cases who underwent NAT, 72 cases accomplished surgical resection. Upfront surgery (UpS) was planned in 216 cases, and surgical resection was accomplished in 199 cases. Resection rate showed no difference between the two groups (P = 0.638). Although NAT group showed a favorable trend in overall survival (OS) compared with the UpS group, the difference was not significant (P = 0.143). carbohydrate antigen 19-9 >500 U/mL and/or duke pancreatic monoclonal antigen type 2 >700 U/mL was defined as high TM. When comparing in TM-high group (n = 83), patients with NAT showed significantly better OS than those without NAT (P = 0.024). In TM-low group (n = 213), the OS curves completely overlapped with no difference (P = 0.902). A multivariate analysis demonstrated that undergoing NAT was the sole independent prognostic factor in the TM-high group (hazard ratio: 0.48, P = 0.044) while undergoing NAT was not a prognostic factor in the TM-low group. Conclusion: The efficacy of NAT for RPC might be limited to the subset of patients with high TM.Keywords
This publication has 27 references indexed in Scilit:
- Randomized phase II trial of chemoradiotherapy with S‐1 versus combination chemotherapy with gemcitabine and S‐1 as neoadjuvant treatment for resectable pancreatic cancer (JASPAC 04)Journal of Hepato-Biliary-Pancreatic Sciences, 2023
- Long-term adjuvant chemotherapy after resection for pancreatic cancer patients with positive peritoneal lavage cytologyLangenbeck's Archives of Surgery, 2023
- Role of neoadjuvant treatment in resectable pancreatic cancer according to vessel invasion and increase of CA19‐9 levelsJournal of Hepato-Biliary-Pancreatic Sciences, 2023
- Importance of triple tumor markers as biomarkers in patients with pancreatic ductal adenocarcinomaAnnals of Gastroenterological Surgery, 2022
- New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery (JSHBPS)Journal of Hepato-Biliary-Pancreatic Sciences, 2021
- Biological and conditional factors should be included when defining criteria for resectability for patients with pancreatic cancerHPB, 2019
- The Impact of Tumor Location on Resection and Survival for Pancreatic Ductal AdenocarcinomaJournal of Surgical Research, 2019
- International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017Pancreatology, 2018
- Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual TargetsJournal of Gastrointestinal Surgery, 2015
- Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancerStrahlentherapie und Onkologie, 2014